|
|
Volumn 47, Issue 10, 2011, Pages 1468-1475
|
|
Heterogeneity in the definition of dose-limiting toxicity in phase i cancer clinical trials of molecularly targeted agents: A review of the literature
|
|
Author keywords
Definition; Dose limiting toxicity; Duration of toxicity; Molecularly targeted agents; NCI CTCAE; Phase I trials; Reversibility
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ADVERSE OUTCOME;
ANEMIA;
ANOREXIA;
ARTHRALGIA;
BLEEDING;
BLOOD CLOTTING DISORDER;
BLOOD TOXICITY;
BRONCHOSPASM;
CANCER PAIN;
CHEMOTHERAPY INDUCED EMESIS;
CONSTIPATION;
DIARRHEA;
DISEASE DURATION;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG ERUPTION;
DRUG FEVER;
DRUG HYPERSENSITIVITY;
DRUG INDUCED HEADACHE;
DRUG INTOXICATION;
ELECTROLYTE DISTURBANCE;
EYE TOXICITY;
FATIGUE;
FEBRILE NEUTROPENIA;
HEART ARRHYTHMIA;
HEART MUSCLE CONDUCTION DISTURBANCE;
HEMATURIA;
HUMAN;
HYPERGLYCEMIA;
HYPERTENSION;
HYPOTENSION;
INJECTION SITE REACTION;
INTERSTITIAL PNEUMONIA;
LIVER TOXICITY;
LUNG TOXICITY;
LYMPHOCYTOPENIA;
MALAISE;
MITRAL VALVE REGURGITATION;
MOLECULARLY TARGETED THERAPY;
MONOTHERAPY;
MULTIPLE CYCLE TREATMENT;
MYALGIA;
NAUSEA;
NEUROTOXICITY;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEINURIA;
QT PROLONGATION;
REVIEW;
SIDE EFFECT;
THROMBOCYTOPENIA;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I AS TOPIC;
DRUG ADMINISTRATION SCHEDULE;
DRUG TOXICITY;
HUMANS;
MAXIMUM TOLERATED DOSE;
MEDICAL ONCOLOGY;
NEOPLASMS;
TOXICITY TESTS;
TREATMENT OUTCOME;
|
|
EID: 79958777006
PISSN: 09598049
EISSN: 18790852
Source Type: Journal
DOI: 10.1016/j.ejca.2011.03.016 Document Type: Article |
|
Times cited : (49)
|
|
References (6)
|
